PUBLICATION
Global Business Reports
Singapore Chemicals 2013
December 19, 2013
Singapore continues to impress. As a wealthy city-state of just 5 million people its chemical sector is constantly threatened by the industries of its regional peers, who boast far larger markets and lower costs. Yet Singapore’s chemical industry is thriving, with a number of major investments planned and a clear vision for the future provided by the country’s Economic Development Board. Singapore undoubtedly faces challenges, yet one should not doubt their ability to meet them.
RELATED INTERVIEWS MORE INTERVIEWS
Haldor Topsoe discusses the potential for energy transition in Latin America.
The Mexican Union of Agrochemicals Manufacturers and Formulators (UMFFAAC) describes the main themes impacting its members.
"Preparing the industry to seize the opportunity is crucial. Just as the US experienced stages during the shale boom, Argentina must follow similar steps."
Cristian García of PROCCYT explains the dynamics influencing Mexico’s crop protecting sector.
RELATED ARTICLES MORE ARTICLES
Solid Demand Factors but Political Risk Rising
Mexico Petrochemicals and Chemicals 2018 APLA Pre-Release
Rising exports and a growing middle class bode well for Mexico’s chemical demand, but NAFTA renegotiations, Presidential elections and the slow pace of energy reforms are present concerns.
Chemical Distribution in Latin America
Latin America Petrochemicals and Chemicals 2024 - Digital Interactive
There is still room for consolidation
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED
MACIG
SUBSCRIBE TO OUR NEWSLETTER
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
